Molecular Partners AG
MP0712
small cell lung cancer
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for MP0712 in small cell lung cancer are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“The Company expects initial clinical data from this study in 2026.”